A NEW TRISYMPTOM COMPOSITE ENDPOINT TO EVALUATE THE EFFICACY OF RIFAXIMIN FOR THE MULTIPLE SYMPTOMS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D): A POOLED ANALYSIS OF TWO RANDOMIZED, PHASE 3 TRIALS

被引：0
|
作者：
Lacy, Brian E.
Sayuk, Gregory S.
Karsan, Hetal A.
Allen, Christopher
Heimanson, Zeev
Brenner, Darren M.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1395
引用
收藏
页码：S756 / S757
页数：2
相关论文
共 50 条
  • [21] RIFAXIMIN FOR IMPROVING ABDOMINAL PAIN AND BLOATING SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) USING MODIFIED DEFINITIONS OF PAIN RESPONSE
    Lacy, Brian E.
    Heimanson, Zeev
    Pimentel, Mark
    GASTROENTEROLOGY, 2019, 156 (06) : S92 - S93
  • [22] Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response
    Lacy, B.
    Heimanson, Z.
    Pimente, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [23] Safety and Tolerability of Rifaximin in the Treatment of Irritable Bowel Syndrome (IBS): A Pooled Analysis of 4 Randomized, Placebo-Controlled Trials
    Lembo, Anthony J.
    Pimentel, Mark
    Wolf, Ray
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S253 - S253
  • [24] EFFECT OF ELUXADOLINE ON ABDOMINAL AND BOWEL SYMPTOMS OVER TIME IN PHASE 3 CLINICAL TRIALS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)
    Harris, L. A.
    Lucak, S.
    Chang, L.
    Dove, L. S.
    Covington, P. S.
    GUT, 2016, 65 : A122 - A123
  • [25] Cilansetron is efficacious in treating diarcheal symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) over 3 months
    Miner, PB
    Pruitt, RE
    Carter, F
    Caras, S
    Krause, G
    Steinborn, C
    GASTROENTEROLOGY, 2005, 128 (04) : A29 - A29
  • [26] Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-analysis of randomized controlled trials
    Wang, Xuesong
    Shi, Xuliang
    Lv, Jing
    Zhang, Juncha
    Huo, Yongli
    Zuo, Guang
    Lu, Guangtong
    Liu, Cunzhi
    She, Yanfen
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [27] ASSESSMENT OF THE SAFETY AND TOLERABILITY OF THE ANTIBIOTIC RIFAXIMIN FOR IRRITABLE BOWEL SYNDROME (IBS): A POOLED ANALYSIS OF THREE PHASE 3 STUDIES
    Chang, Christopher
    Pimentel, Mark
    Heimanson, Zeev
    Lacy, Brian E.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S122 - S122
  • [28] Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points
    Lacy, Brian E.
    Chang, Lin
    Rao, Satish S. C.
    Heimanson, Zeev
    Sayuk, Gregory S.
    CLINICAL THERAPEUTICS, 2023, 45 (03) : 198 - 209
  • [29] Cilansetron a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D)
    Coremans, G
    Clouse, RE
    Carter, F
    Krause, G
    Caras, S
    Steinborn, C
    GASTROENTEROLOGY, 2004, 126 (04) : A643 - A643
  • [30] CHARACTERIZATION OF LONG-TERM RIFAXIMIN RESPONDERS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED REPEAT TREATMENT TRIAL FOR DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)
    Weinstock, Leonard
    Pimentel, Mark
    Heimanson, Zeev
    Lembo, Anthony J.
    GASTROENTEROLOGY, 2018, 154 (06) : S498 - S498
12345